Compass Pathways Aktie

Compass Pathways ROCE

ROCE (Return on Capital Employed) for Compass Pathways (CMPS) pr. 26. jul. 2026 er 338,78 %. I foregående år var ROCE (Return on Capital Employed) -115,20 % — en ændring på -394,08 % (højere).

ROCE

338,78 %

YoY

-394,08%

Senest opdateret:

I år 2026 var afkastet på den investerede kapital (ROCE) for Compass Pathways 338,78 %, en stigning på -394,08% sammenlignet med -115,20 % ROCE det foregående år.

Access this data via the Eulerpool API

Compass Pathways Aktieanalyse

Hvad laver Compass Pathways? Compass Pathways PLC is a leading company specializing in the development of groundbreaking therapies for the treatment of mental illnesses. The company was founded in 2016 and is headquartered in London. Its goal is to revolutionize the treatment of depression and other mental illnesses. The business model of Compass Pathways is based on researching psychedelics as a potential treatment for patients suffering from severe depression and anxiety disorders. The company uses innovative approaches to precisely study the effects of psychedelics on the human brain and develop new therapy concepts and products from that. An important area of Compass Pathways is clinical research. The company collaborates closely with leading research institutions to understand the impacts of psychedelics on the human brain. The research results are then used to develop innovative methods for therapeutic use of psychedelics. Another important area of Compass Pathways is the development of therapeutic products. The company has developed a patented process for producing psilocybin, a substance found in hallucinogenic mushrooms. This process achieves a very high purity of the substance, enabling precise dosing and better control of its effects. The flagship product of Compass Pathways is COMP360, a medication based on psilocybin that is being developed for the treatment of depression. The medication is currently in clinical Phase 2 trials, showing promising results. If COMP360 receives approval, it has the potential to drastically change the way we treat depression. Compass Pathways is also active in other areas. The company conducts a range of research projects related to various psychedelic substances, including LSD and other hallucinogens. Another important area of Compass Pathways is training therapists and other professionals in the use of psychedelic substances. The company offers relevant courses to promote understanding of the therapeutic use of psychedelics and enable their safe and effective application for patient treatment. Overall, Compass Pathways is a company focused on the development of groundbreaking therapies for mental illnesses. Through combining cutting-edge research, innovative products, and professional education, the company has the potential to revolutionize the way we treat mental illnesses. Compass Pathways er et af de mest populære virksomheder på Eulerpool.com.

ROCE i detaljen

Afkodning af afkastet på den investerede kapital (ROCE) for Compass Pathways

Afkastet på den investerede kapital (ROCE) for Compass Pathways er en finansiel nøgletalsindikator, der måler rentabiliteten og effektiviteten af virksomhedens brug af den investerede kapital. Det beregnes ved at dividere resultatet før renter og skat (EBIT) med den investerede kapital. En højere ROCE antyder, at virksomheden anvender sin kapital effektivt for at skabe overskud.

Sammenligning år til år

Den årlige analyse af ROCE for Compass Pathways giver værdifulde indsigter i dets effektivitet i brugen af kapitalen til indtjening. En stigende ROCE indikerer en forbedret rentabilitet og driftseffektivitet, mens en dalende ROCE kan signalere potentielle problemer i anvendelsen af kapitalen eller i forretningsdriften.

Indvirkninger på investeringer

ROCE for Compass Pathways er en kritisk faktor for investorer og analytikere, når de vurderer virksomhedens effektivitet og rentabilitet. En højere ROCE kan gøre virksomheden til en attraktiv investering, fordi det ofte indikerer, at virksomheden genererer tilstrækkelige overskud fra den kapital, der er investeret.

Fortolkning af svingninger i ROCE

Ændringer i ROCE for Compass Pathways kan skyldes variationer i EBIT eller den investerede kapital. Disse fluktuationer giver indsigt i virksomhedens operationelle effektivitet, finansielle performance og strategisk finansstyring, og de støtter investorerne i at træffe informerede beslutninger.

Hyppigt stillede spørgsmål om Compass Pathways aktie

ROCE (Return on Capital Employed) for Compass Pathways er 338,78 % i 2026.

Access this data via the Eulerpool API

Rentabilitet — Compass Pathways

Alle nøgletal — Compass Pathways